L-leucine in Diamond Blackfan Anemia Patients

NCT02386267 | Unknown Phase 2

• 1 other identifier: Ru0001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Diamond-Blackfan anemia (DBA) is a rare congenital syndrome associated with physical anomalies, short stature, red cell aplasia, and an increased risk of malignancy. Mutations affecting genes encoding ribosomal proteins cause DBA. Genetic studies have identified heterozygous mutations in at least one of eight ribosomal protein genes in up to 50% of cases. 25% of patients carry a mutation in the ribosomal protein (RP)S19 gene, whereas mutations in RPS24, RPS17, RPL35A, RPL11, and RPL5 are rare. p53 activation has been identified as a key component in the pathophysiology of DBA after cellular and molecular studies. Other potential mechanisms that warrant further investigation include impaired translation as the result of ribosomal insufficiency, which may be ameliorated by Leucine supplementation. Despite significant improvements in understanding of the pathophysiology of Diamond Blackfan anemia (DBA), there have been few advances in therapy. The cornerstones of treatment remain corticosteroids,chronic red blood cell transfusions, and hematopoietic stem cell transplantation, each of which is fraught with complications. Other treatments have been shown to be effective in only a few patients or in individual case reports : IL-3, cyclosporine (alone or in combination with steroids), metaclopramide. Gene therapy is still a part of research programs. There are some indications that the Amino Acid (AA) L-leucine, a translation enhancer, may have some efficacy in DBA and 5q-syndrome, which has the same altered ribosome functions as the DBA. L-leucine is an essential AA that is unique among the branched-chain AA acting as a nutrient regulator of protein synthesis in skeletal muscle and adipose tissue. Several preclinical studies with DBA lymphocytes exposed to various L-leucine doses, have demonstrated that protein synthesis can be increased by using high doses L-leucine. Recent clinical data on L-leucine therapeutic use have demonstrated increase the hemoglobin level and transfusion independence in patients with DBA and 5q-syndrom. These data support the rationale for clinical trial on L-leucine use as a therapeutic agent for DBA patients.

Conditions

Diamond Blackfan Anemia

Outcome Measures

Primary Outcomes (1)

• Hemoglobin level

  Response to the treatment can be one of the following: 1. Complete response (CR): Hb \> 9 gm/dL and transfusion-independence as defined in DBA 2. Partial response (PR): Hb \< 9 gm/dL, increased reticulocyte count \> 1% and any increase in transfusion interval from baseline. 3. No response (NR): no change in transfusion requirements and no significant change in Hb or reticulocytes 4. Progression: worsening of disease as defined by the need for more frequent transfusions

  every 4 weeks for 12 months

Secondary Outcomes (1)

• Side effects of L-leucine in transfusion-dependent DBA patients for one year

  every 4 weeks for 12 moths

Study Arms (1)

L-leucine pills

EXPERIMENTAL

L-leucine , dose- 700mg/m2 , per os, three time a day, course duration 6 months

Drug: L-leucine

Interventions

L-leucine DRUG

L-leucine pills per os for 6 months

L-leucine pills

Eligibility Criteria

• Age: 1 Year - 20 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• signed Informed Consent Form
• diagnosed Diamond Blackfan Anemia
• transfusion dependenсe
• adequate renal function
• adequate liver function
• negative B-HCG and adequate contraception

You may not qualify if:

• known hypersensitivity to branched chain amino acids
• diagnosed AA metabolism disorder
• prior HSCT
• pregnancy or planning to become pregnant

Sponsors & Collaborators

• Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache: lead

Study Sites (1)

Federal Scientific Clinical Centre of Pediatric Hematology Oncology Immunology n.a. Dmitry Rogachev

Moscow, 117997, Russia

RECRUITING

MeSH Terms

Conditions

Anemia, Diamond-Blackfan

Interventions

Leucine

Condition Hierarchy (Ancestors)

Anemia, Hypoplastic, Congenital; Anemia, Aplastic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Red-Cell Aplasia, Pure; Congenital Bone Marrow Failure Syndromes; Bone Marrow Failure Disorders; Bone Marrow Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Amino Acids, Branched-Chain; Amino Acids; Amino Acids, Peptides, and Proteins; Amino Acids, Essential

Study Officials

• Natalia - SMETANINA, MD, PhD

  FSCCPHOI, Outpatient Department

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Natalia - SMETANINA, MD, PhD

CONTACT

+7 985 647 13 05; Nataliya.Smetanina@fccho-moscow.ru

Galina - OVSYANNIKOVA, PhD

CONTACT

+7 916 238 13 57; galina.ovsyannikova@fccho-moscow.ru

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 18, 2015
• First Posted: March 11, 2015
• Study Start: September 1, 2014
• Primary Completion: March 1, 2015
• Study Completion: March 1, 2016
• Last Updated: March 11, 2015

Record last verified: 2015-03

Locations

RU (1)